Dayan JH, Ly CL, Kataru RP, Mehrara BJ, et al.
Annual review of medicine. Date of publication 2018 Jan 29;volume 69():263-276.
1. Annu Rev Med. 2018 Jan 29;69:263-276. doi: 10.1146/annurev-med-060116-022900.
Epub 2017 Sep 6.
Lymphedema: Pathogenesis and Novel Therapies.
Dayan JH(1)(2), Ly CL(1), Kataru RP(1), Mehrara BJ(1)(2).
Author information:
(1)Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial
Sloan Kettering Cancer Center, New York, NY 10065; email: dayanj@mskcc.org ,
lyc@mskcc.org , katarur@mskcc.org , mehrarab@mskcc.org.
(2)Plastic and Reconstructive Surgery Service, Department of Surgery, Weill
Cornell Medical College, New York, NY 10065.
Lymphedema affects up to 1 in 6 patients who undergo treatment for a solid tumor
in the United States. Its prevalence has increased as more effective oncologic
therapies have improved patient survival, but there remains no definitive cure.
Recent research has elucidated new details in the pathogenesis of the disease and
has demonstrated that it is fundamentally an immunologic process that ultimately
results in inflammation, fibroadipose deposition, impaired lymphangiogenesis, and
dysfunctional lymphatic pumping. These findings have allowed for the development
of novel medical and surgical therapies that may potentially alter the standard
of care for a disease that has largely been treated by compression. This review
seeks to provide an overview of the emerging therapies and how they can be
utilized for effective management of lymphedema.
DOI: 10.1146/annurev-med-060116-022900
PMID: 28877002
